Fallouh Healthcare, a medical device startup, has secured $407,725 in its latest funding round. This investment will support the company's mission to enhance patient safety and outcomes following cardiac surgery. Fallouh Healthcare is focused on developing innovative solutions to critical challenges in postoperative care, particularly addressing the life-threatening condition of cardiac tamponade.
Cardiac tamponade, caused by blood clot collection compressing the heart, is a serious complication that can arise after cardiac surgery, leading to significant morbidity and mortality if missed. Current diagnostic methods are often subjective, delayed, and necessitate invasive procedures to confirm or exclude the condition. Fallouh Healthcare's flagship product, PerDeCT™, aims to revolutionize this diagnostic process. Developed by a practicing cardiothoracic surgeon, PerDeCT™ is designed as a dedicated device to accurately diagnose cardiac tamponade while also providing crucial cardiac output measurements.
The capital raised in this funding round will be instrumental in accelerating the advancement of PerDeCT™. These funds are earmarked to progress product development, support necessary regulatory processes, and lay the groundwork for potential clinical trials and market introduction. This investment highlights growing confidence in Fallouh Healthcare’s technology and its potential to address a significant unmet medical need.
With this new funding, Fallouh Healthcare is poised to move closer to its goal of delivering a device that promises earlier and more accurate diagnosis of cardiac tamponade. This could lead to a reduction in mortality rates, improved patient outcomes, and substantial cost savings for healthcare systems by preventing unnecessary operations and mitigating the severe consequences of delayed diagnosis. The company is committed to transforming postoperative cardiac care through innovative medical technology.
.png&w=3840&q=75)
